Amgen

Open: 272.07 Close: 269.86 Change: -2.21

How to know if Amgen Company Inc is a risky investment without reading the whole internet.

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, market, academic, Revenue, medicine, first, engage, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Federal Trade Commission said the deal would enable Amgen to exploit its size to block competition for two expensive Horizon drugs. FTC and six states filed a lawsuit claiming that the acquisition would give Amgen incentive.

Today's News

Federal Trade Commission said the deal would enable Amgen to exploit its size to block competition for two expensive Horizon drugs. U.S. markets close in 5 hours 25 minutes S&P 500 4,362.44 -39.76 (-0.76%) Dow 30 34,309.28 -131.60 (-131.28%) Russell 2000 1,791.85 -18.25 (-1.01%) Crude Oil 90.53 +0.87 (+0.97%) Gold 1,941., but ref polite whip lament VPN fodder had nailsradoryrights este improvements investments Amgen launches partners of choice network of eight leading oncology academic centers. Network fosters academic collaboration to advance new treatment options for patients with greatest unmet needs. Revenue for Ustekinumab Biosimilar expected to reach annual total of $600 mn by 2027 globally based off GlobalDatas Revenue Model. Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative medicines. The Amgen Foundation started operating in 1991, just a little over a decade after Amgen landed on the biotech scene and just one year after its first medicine came on the market. Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Amgen Inc. (AMGN) Investigation concerns whether Amgen and certain of its officers and/or directors have engaged in corporate wrongdoing. Investors who purchased Amgen securities prior to July 29, 2020, and continue to hold to the present, are encouraged to obtain additional information. The Senior Specialty Representative acts as the primary customer contact and is responsible for executing marketing strategy and promoting Amgen products. Amgen is an Equal Opportunity employer. Manager Manufacturing (Downstream) in Holly Springs, North Carolina. Amgen FleX Batch facility will combine the latest in disposable technologies with traditional stainless-steel equipment to allow for maximum flexibility in operations. The FTC and six states filed a lawsuit claiming that the acquisition would give Amgen incentive to engage in cross-product bundling that would exclude Horizons rivals and maintain its monopolies. Amgen is the first FTC conduct remedy settlement under current leadership. Amgen stock has received a consensus rating of hold. The 64 analysts offering price forecasts for Amgen have a median target of 251.88, with a high estimate of 320.00 and a low estimate of 182.00. According to the current price, Amgen is 127.68%.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, market, academic, Revenue, medicine, first, engage, and the most common words in the summary are: amgen, stock, market, inc, job, news, price, . One of the sentences in the summary was: Federal Trade Commission said the deal would enable Amgen to exploit its size to block competition for two expensive Horizon drugs. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #market #inc #job #news #price.